AstraZeneca PLC (AZN) Insurance Fraud in China Case

• $AZN investors filed a lawsuit against AstraZeneca PLC for misleading them about its compliance with regulations and understated legal risks in China.

• On November 5, 2024, reports revealed widespread insurance fraud involving AstraZeneca's employees in China. Following this news, $AZN dropped by 7.2%.

• $AZN investors can join this case to be notified about potential recovery.

Case Details:

Between February 23, 2022, and December 17, 2024, AstraZeneca reassured its investors about maintaining strong compliance with global legal and regulatory standards. However, a whistleblower report and subsequent investigations uncovered serious issues within AstraZeneca’s China division. Employees committed widespread insurance fraud by forging prescriptions for the lung cancer drug Tagrisso and falsifying genetic test reports, causing significant losses to China's state health insurance fund over several years.

On October 30, 2024, AstraZeneca revealed that its China President, Leon Wang, was under investigation by Chinese authorities. Despite the company's attempts to downplay the issue, on November 5, 2024, it was uncovered that numerous employees and executives were implicated in China's largest pharmaceutical insurance fraud case.

Following this, $AZN dropped over 7%.

Based on these events, $AZN investors filed a lawsuit against AstraZeneca PLC, claiming the company:

• It misled investors about its regulatory compliance and exposure to legal risks in China.

• It downplayed the severity and potential consequences of ongoing investigations.

Investors believe AstraZeneca failed to disclose its legal vulnerabilities in China.